Cetuximab-Induced Rash in a 54-Year-Old with SCC

Chief Complaint

MJ, a 54-year-old male diagnosed with squamous cell carcinoma (SCC) of the oropharynx (T4aN2bMx), develops grade 3 acneiform rash (Slide 1) after receiving an investigational treatment containing cetuximab.

History and Physical

• MJ is currently enrolled in a clinical trial with therapy consisting of continuous infusion 5-fluorouracil, carboplatin, and cetuximab.

• After receiving the second dose of cetuximab therapy, MJ noticed the ...